Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.

China Life Healthcare Fund and Venus Medtech have taken part in a round for the heart valve treatment developer sized in the hundreds of millions of dollars.

GV was among the investors in a series A round led by Andreessen Horowitz closed three years after the gene therapy developer's launch.

The Coinbase, Ripple and Monex-backed Latin American crypto trading platform was valued at $2.2bn in a round co-led by Tiger Global Management and Coatue Management.

Workday Ventures has returned to back the telehealth platform developer’s series D round, which included Axa Venture Partners, Centene and GuideWell.

Ericsson and Maersk Growth were among the investors in the autonomous logistics vehicle developer's series B round.

The Chernin Group led the health tracker producer's series C round, which also featured Square and Eisai, at an $800m valuation.

GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.

CU Boulder’s solid-state battery provider pulled in funding through a series B round co-led by potential customers BMW and Ford.

The health benefits software provider pushed its valuation to $1.5bn in a series F round led by Health Care Service Corporation and backed by Sun Life and SoftBank.